Beneficial effects of prolonged systemic administration of PIGF on late outcome of post-ischaemic myocardial performance

Journal of Pathology

Volumn 216, Issue 2, 2008, Pages 236-244

  Roncal, C ^a,b   Buysschaert, I ^a,b   Chonanopoulos, E K ^a,b   Georgiadou, M ^a,b   Meilhac, O ^c   Demol, M ^a,b   Michel, J B ^c   Vinckier, S ^a,b   Moons, L ^a,b   Carmeliet, P ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BICHAT HOSPITAL   (France)

Author keywords

Adenoviral gene transfer; Angiogenesis; Hypertrophy; Myocardial infarction; PIGF

Indexed keywords

ADENOVIRUS VECTOR; PLACENTAL GROWTH FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY LIGATION; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE PERFUSION; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 53149097323     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2408     Document Type: Article

References (45)

1. Cleland JG, Khand A, Clark A. The heart failure epidemic; exactly how big is it? Eur Heart J 2001;22:623-626.
2. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108- 2118.
3. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis; initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
4. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study; the Euroinject One trial. J Am Coll Cardiol 2005;45:982-988.
5. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease; a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-1511.
6. Vera Janavel G, Crottogini A, Cabeza Meckert P. Cuniberti L, Mele A, Papouchado M, et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Ther 2006; 13:1133-1142.
7. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J Am Coll Cardiol 2000;35:1323-1330.
8. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267:H1948-H1954.
9. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47:887-893.
10. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 2006;101:204-213.
11. Yang R, Bunting S, Jin H. Effects of VEGF on hemodynamics and cardiac function; characterization and mechanisms. IDrugs 2000;3;1346- 1352.
12. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium; deleterious effects of unregulated expression. Circulation 2000;102;898-901.
13. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia; phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-2683.
14. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial; Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107;1359-1365.
15. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89;2183-2189.
16. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, et al. Pharmacodynamics of basic fibroblast growth factor; route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997;36:78-85.
17. Markkanen JE, Rissanen TT, Kivela A, Yla-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart - gene therapy. Cardiovasc Res 2005;65:656-664.
18. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med 2001;7:575-583.
19. Scholz D, Elsaesser H, Sauer A, Friedrich C, Luttun A, Carmeliet P, et al. Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (P1GF) -/- mice. J Mol Cell Cardiol 2003;35:177-184.
20. Babiak A, Schumm AM, Wangler C, Loukas M, Wu J, Dombrowski S, et al. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovasc Res 2004;61:789-795.
21. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, et al. VEGFR-1-selective VEGF homologue P1GF is arteriogenic; evidence for a monocyte-mediated mechanism. Circ Res 2003;92:378-385.
22. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fltl. Nature Med 2002;8:831-840.
23. Roy H, Bhardwaj S, Babu M, Jauhiainen S, Herzig KH, Bellu AR, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005;16:1422-1428.
24. Kolakowski S Jr, Berry MF, Atluri P, Grand T, Fisher O, Moise MA, et al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg 2006;21:559-564.
25. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med 1999;5:1135-1142.
26. Gao XM, Xu Q, Kiriazis H, Dart AM, Du XJ. Mouse model of post-infarct ventricular rupture; time course, strain- and genderdependency, tensile strength, and histopathology. Cardiovasc Res 2005;65:469-477.
27. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-512.
28. Lutgens E, Daemen MJ, de Muinck ED, Debets J, Leenders P, Smits JF. Chronic myocardial infarction in the mouse; cardiac structural and functional changes. Cardiovasc Res 1999;41:586-593.
29. Tirziu D, Chorianopoulos E, Moodie KL, Palac RT, Zhuang ZW, Tjwa M, et al. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest 2007;117:3188-3197.
30. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006;99:715-722.
31. Gigante B, Morlino G, Gentile MT, Persico MG, De Falco S. Plgf-/-eNos -/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB J 2006;20:970-972.
32. Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, et al. 15-Lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res 2008;102:177-184.
33. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, et al. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol 2008;294:H1381-H1387.
34. Szukiewicz D, Szewczyk G, Watroba M, Kurowska E, Maslinski S. Isolated placental vessel response to vascular endothelial growth factor and placenta growth factor in normal and growthrestricted pregnancy. Gynecol Obstet Invest 2005;59:102-107.
35. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of D114 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-1087.
36. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of D114 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-1037.
37. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169;681-691.
38. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-1177.
39. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002;109:327-336.
40. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996;97:469-476.
41. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002;115:2559- 2567.
42. Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003;101:560-567.
43. Iwama H. Uemura S. Naya N. Imagawu K. Takemoto Y. Asai O. et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 2006;47:I559-1567.
44. Simons M. Annex BH. Lahum RJ. Kleimun N. Henry T. Dauerman H. et al. Pharmacological treatment of coronary artery disease with recombinant fibroblasl growth factor-2; double-blind, randomized. controlled clinical trial. Circulation 2002;105:788-793.
45. Crines CL. Walkins MW. Mahmarian JJ. Iskandrian AE. Rade JJ. Marrott P. et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42;1339-1347.